Journal Guides10 min read•Updated Mar 16, 2026

Annals of Oncology Submission Guide: Requirements & What Editors Want

Annals of Oncology's submission process, first-decision timing, and the editorial checks that matter before peer review begins.

By Associate Professor, Clinical Medicine & Public Health•March 16, 2026

Associate Professor, Clinical Medicine & Public Health

Author context

Specializes in clinical and epidemiological research publishing, with direct experience preparing manuscripts for NEJM, JAMA, BMJ, and The Lancet.

Readiness scan

Before you submit to Annals of Oncology, pressure-test the manuscript.

Run the Free Readiness Scan to catch the issues most likely to stop the paper before peer review.

Run Free Readiness ScanAnthropic Privacy Partner. Zero-retention manuscript processing.Open Annals of Oncology Guide

Stage	What to check
1. Scope	Manuscript preparation
2. Package	Submission via ESMO system
3. Cover letter	Editorial assessment
4. Final check	Peer review

Decision cue: If you're targeting Annals of Oncology with your oncology research, compare your study design against their recent clinical trial publications and only submit when you have multi-center data, mature efficacy endpoints, and mechanistic insight explaining treatment outcomes.

This guide focuses on the part that matters most for Annals of Oncology: not whether the files are neat, but whether the study already looks decisive enough for a very selective oncology desk screen.

Quick answer

Annals of Oncology accepts 10-20% of submissions with median review time of 90-120 days. The journal prioritizes multi-center clinical trials, biomarker validation studies, and translational research with mechanistic insight. Word limit is 4,000 words for original articles. Common desk rejections: single-center studies, phase 1/2 trials without mature efficacy data, and biomarker claims without independent validation.

Quick answer: is your paper ready for Annals of Oncology?

Annals of Oncology does not reward exploratory oncology studies dressed up as practice-changing papers. The journal wants findings that could plausibly influence treatment decisions, biomarker use, or clinical strategy.

Your paper needs three elements to clear the desk rejection filter. First, multi-center validation. Single-center studies get rejected unless they're reporting novel mechanisms in rare cancers with patient numbers that justify the limitation. Second, mature efficacy data. Phase 1/2 dose-escalation studies without response or survival endpoints don't make the cut. Third, mechanistic understanding. Whether you're reporting biomarker associations or treatment responses, explain why the biology works.

The journal’s selectivity reflects that editorial position. It competes with other top oncology titles for the same strong clinical and translational papers, so your study needs to move treatment thinking forward rather than add another loose association.

Check your patient numbers against their recent publications. Most accepted clinical trials include 200+ patients across multiple centers. Biomarker studies typically validate findings in independent cohorts of 100+ patients each.

Annals of Oncology Submission Requirements

Manuscript specifications:

Original articles: 4,000 words maximum (excluding references, figures, tables)
Abstract: 250 words structured (Background, Methods, Results, Conclusions)
References: Vancouver style, maximum 50 for original articles
Figures: maximum 6 for original articles, minimum 300 DPI resolution
Tables: maximum 4 for original articles

Required documents:

Cover letter (no word limit specified)
Conflict of interest disclosure for all authors
Ethics approval documentation
Patient consent statements (when applicable)
Data sharing statement
Author contribution statements (CRediT taxonomy accepted)

Clinical trial specific requirements:

ESMO requires trial registration before first patient enrollment. Include registration number in abstract and methods. For randomized trials, follow CONSORT guidelines completely. This means patient flow diagrams, baseline characteristics tables, and intention-to-treat analyses.

Phase 3 trials need pre-specified statistical analysis plans submitted with original protocol. Don't submit preliminary analyses from ongoing trials unless you're reporting safety data or interim efficacy results that change clinical practice.

Biomarker studies require pre-analytical variables documentation. Sample collection, storage conditions, assay validation, and quality control measures must be detailed. The journal desk-rejects biomarker papers without independent validation cohorts.

Technical formatting:

Submit through Editorial Manager. File formats accepted: Word (.doc/.docx), LaTeX, RTF for manuscripts. TIFF, EPS, PDF for figures at 300+ DPI. No PowerPoint figures accepted.

Line numbering is required. Double-space everything including references. Use Times New Roman 12-point font. Number pages consecutively.

The journal charges €4,200 ($4,500) article processing charge for accepted papers. No submission fees.

What Annals of Oncology Editors Actually Want

Annals of Oncology editors filter submissions through ESMO's clinical priorities: precision oncology, immunotherapy combinations, biomarker-guided treatment selection, and survival endpoint improvements.

Clinical trials that get accepted:

Multi-center phase 2/3 trials with mature efficacy data. Not dose-escalation studies or safety run-ins. The editors want response rates, progression-free survival, or overall survival data that could change treatment guidelines. Single-arm studies get accepted only for rare cancers or novel mechanisms where randomized comparisons aren't feasible.

Recent examples include combination immunotherapy trials with 12+ month follow-up, biomarker-selected targeted therapy studies, and resistance mechanism investigations with clinical validation.

Translational research priorities:

The journal publishes mechanistic studies that explain clinical observations. Why do some patients respond to checkpoint inhibitors while others don't? What drives resistance to targeted therapies? How do tumor microenvironment changes predict treatment outcomes?

Your translational study needs clinical correlation. Pure bench science belongs in Cancer Research or Nature Cancer. Annals of Oncology wants translational findings that inform treatment decisions.

Biomarker validation standards:

Discovery cohort plus independent validation cohort, minimum 100 patients each. Prospective sample collection preferred over retrospective analyses. Pre-analytical variables documented completely. Assay reproducibility data included.

The editors reject biomarker studies that report associations without functional validation. Correlative analyses from clinical trials need mechanistic explanation of why the biomarker predicts response.

What triggers immediate desk rejection:

Case reports and small case series (fewer than 20 patients). Meta-analyses without individual patient data. Review articles without invitation. Economic analyses without clinical trial data. Preclinical studies without clinical validation.

Laboratory studies using cell lines or animal models get rejected unless they're validating clinical biomarker findings or explaining resistance mechanisms observed in patients.

Editorial decision factors:

Sample size calculations with power analyses. Multi-center patient recruitment demonstrating generalizability. Mature follow-up periods appropriate for the endpoints. Statistical methods appropriate for the study design.

The editors prioritize studies that advance precision oncology. Biomarker-guided treatment selection, resistance mechanism identification, and combination therapy rationale design get preference over empirical treatment comparisons.

Competition from Lancet Oncology and JAMA Oncology means your clinical finding needs immediate practice-changing potential. Incremental improvements in existing treatments face tougher acceptance standards than novel therapeutic approaches or biomarker discoveries.

Step-by-Step Submission Process

Access the Editorial Manager portal at www.editorialmanager.com/annonc. Create an account using your institutional email address. Personal email addresses trigger editorial scrutiny.

Step 1: Manuscript type selection

Choose "Original Article" for clinical trials and translational research. "Short Communication" for brief clinical reports (1,500 words maximum). "Letter to Editor" for clinical observations or methodology comments.

Step 2: Author information entry

List corresponding author first, then all co-authors in publication order. Include ORCID IDs for all authors (required, not optional). Add institutional affiliations exactly as they should appear in publication.

Step 3: Manuscript details

Enter title exactly as written in manuscript. Select subject categories from dropdown menus (maximum 3). Primary category should match your study type: "Clinical Trials" for therapeutic studies, "Biomarkers" for predictive marker research.

Add keywords (6-8 recommended). Include MeSH terms where applicable. Keywords help editorial triage and peer reviewer selection.

Step 4: File uploads

Upload manuscript file first (Word or LaTeX). Then figures as separate files (TIFF or EPS format, 300+ DPI). Upload tables as Word documents or Excel files.

Cover letter uploads as separate document. Include conflict of interest forms, ethics approvals, and supplementary materials as additional files.

Step 5: Submission checklist

The system generates an automated checklist. Common missing items: line numbers, page numbers, reference formatting, figure legends, table titles.

Technical troubleshooting:

Large files (>10MB) need compression. The system accepts ZIP files for multiple figure uploads. PDF conversion happens automatically after upload completion.

Browser compatibility issues occur with Internet Explorer. Use Chrome, Firefox, or Safari for stable upload performance.

Submit between 9 AM - 5 PM Central European Time for fastest editorial manager response times.

Cover Letter Strategy for Annals of Oncology

Your cover letter needs three paragraphs: clinical significance, study design strengths, and mechanistic insight.

Paragraph 1: Clinical impact statement

Open with patient population size and current treatment limitations. "Approximately 40,000 patients with metastatic triple-negative breast cancer lack effective treatment options after first-line chemotherapy failure." Then state your clinical finding directly. "Our multi-center trial demonstrates 18.2-month median overall survival with combination immunotherapy versus 11.1 months with standard care."

Paragraph 2: Study design justification

Explain why your approach addresses previous study limitations. Multi-center recruitment, patient selection criteria, primary endpoint selection, and follow-up duration. "Unlike previous single-center studies with heterogeneous patient populations, our trial enrolled 312 patients across 15 centers with standardized biomarker testing and 24-month minimum follow-up."

Paragraph 3: Mechanistic contribution

Connect clinical findings to biological mechanisms. Why did your treatment work? What biomarkers predict response? How do your findings advance precision oncology? "Correlative studies identify PD-L1 combined expression score as predictive biomarker, with response rates of 67% in high-expressing tumors versus 23% in low-expressing tumors."

Template structure:

"Dear Editors, [Clinical problem and your solution]. [Study design that addresses limitations]. [Mechanistic insights that advance the field]. This work advances precision oncology for [specific patient population] and would interest your readership focused on biomarker-guided cancer treatment."

Don't mention journal impact factor or readership size. The editors know their own journal's influence.

Common Submission Mistakes That Trigger Desk Rejection

Inadequate patient numbers without justification. Single-center studies with fewer than 50 patients get rejected unless you're studying rare cancers or novel resistance mechanisms. Biomarker studies need discovery and validation cohorts of 100+ patients each.

Immature efficacy data from ongoing trials. Don't submit interim analyses unless they meet pre-specified efficacy boundaries or report unexpected safety signals. Phase 1 dose-escalation data without response rates or survival outcomes gets desk-rejected.

Missing mechanistic explanation. Clinical observations without biological rationale don't make the cut. If your biomarker predicts treatment response, explain why. If your combination therapy works, describe the mechanism of synergy.

Single biomarker studies without independent validation. Discovery-phase biomarker associations need confirmation in separate patient cohorts. Retrospective correlative analyses from single trials aren't sufficient for Annals of Oncology publication standards.

Inadequate statistical power calculations. Studies designed for hypothesis generation rather than definitive answers get rejected. Your sample size needs adequate power for the primary endpoint analysis.

Incomplete clinical trial reporting. Missing CONSORT diagrams, baseline characteristics without statistical comparisons, or intention-to-treat analyses that exclude protocol violations.

Review Timeline and What to Expect

Initial editorial screening takes 7-14 days. Papers that clear desk rejection go to associate editors for reviewer assignment. Reviewer invitations go out within 21 days of submission.

Review timeline breakdown:

Editorial screening: 7-14 days
Reviewer assignment: 14-21 days
First reviews submitted: 60-90 days
Editorial decision: 90-120 days median

Status meanings:

"Under Review" means peer reviewers are evaluating your manuscript. "Required Reviews Completed" indicates all reviewer reports are submitted and editors are making decisions. "Minor Revision" requests typically allow 30 days for response. "Major Revision" allows 90 days.

When to follow up:

Contact the editorial office if your submission shows "Under Review" for more than 120 days. Don't inquire before 90 days unless you have urgent clinical trial publication timelines.

Reviewers occasionally decline invitations, extending timelines. The editors prioritize thorough review over speed, especially for practice-changing clinical trials.

Accept/reject decisions typically arrive within 10 days of "Required Reviews Completed" status. Revision decisions may take longer if editors request additional statistical review or seek oncology subspecialist input.

Production timeline for accepted papers: 4-6 weeks from final acceptance to online publication. Print publication follows within 2-3 months.